Evaluation of galectin-3 expression by sarcomas, pseudosarcomatous and benign lesions of the soft tissues. Preliminary results of an immunohistochemical study.

Giulio Bigotti(Università Cattolica del Sacro Cuore), Guido Massi(Università Cattolica del Sacro Cuore), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonella Coli(Università Cattolica del Sacro Cuore)

PubMed

June 1, 2003

Cited by 3

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

|New England Journal of Medicine|2017|2.2k

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

|The Lancet Oncology|2017|780

Interleukin-12: Biological Properties and Clinical Application

|Clinical Cancer Research|2007|606

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

|The Lancet Oncology|2020|530

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

|The Lancet Oncology|2017|501